Result of General Meeting
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that all resolutions proposed at the General Meeting held earlier today were duly passed.
Further announcements regarding the proposed Distribution in Specie will be made in due course.
For further information, please contact:
|
Open Orphan plc |
|||
|
Cathal Friel, Executive Chairman |
+353 (0) 1 644 0007 |
||
|
|
|
||
|
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0) 20 7614 5900 |
||
|
John Llewellyn-Lloyd / Benjamin Cryer / Nick Wright |
|
||
|
|
|
||
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 0500 |
||
|
Geoff Nash / James Thompson/ Richard Chambers |
|
||
|
|
|
||
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0) 1 679 6363 |
||
|
Anthony Farrell |
|
||
|
|
|
||
|
Walbrook PR (Financial PR & IR) |
+44 (0)20 7933 8780 or openorphan@walbrookpr.com |
||
|
Paul McManus / Sam Allen / Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7748 651 727 / +44 (0)7584 391 303 |
||